Your session is about to expire
← Back to Search
Utomilumab + Cetuximab + Irinotecan for Colorectal Cancer
Study Summary
This trial is studying the best dose and side effects of irinotecan hydrochloride given with utomilumab and cetuximab to treat patients with metastatic colorectal cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have certain autoimmune disorders or conditions that weaken your immune system, except if you have mild psoriasis that is under control or mild autoimmune thyroiditis that is managed with medication.You have another type of cancer that is currently growing, except for non-melanoma skin cancer or early-stage cervical cancer.If you have a specific type of colorectal cancer with high microsatellite instability, you need to have already received a certain type of medication before joining this trial.You have experienced a severe allergic reaction to antibodies or infused proteins in the past, or you have had a severe allergic reaction to any of the substances in the study drug.You have been diagnosed with ovarian failure by a doctor.You have a serious medical or mental health condition, or a recent history of suicidal thoughts or behavior that could affect your safety or the study results.
- Group 1: Treatment (irinotecan hydrochloride, cetuximab, utomilumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How has Pharmacodynamic Study been applied to improve medical treatments?
"Pharmacodynamic Study provides a potential solution for malignant pancreas neoplasms, metastatic cancer and radiation therapy."
Is the Pharmacodynamic Study compliant with FDA regulations?
"Due to the limited evidence surrounding efficacy and safety, a score of 1 was assigned by our team at Power in regards to pharmacodynamic study."
Are there currently any openings in this clinical experiment?
"Unfortunately, this specific trial is not currently taking in any new patients. Initially posted on December 27th 2017 and last updated August 4th 2022, it has temporarily closed its recruitment window. Currently, 858 trials are open for colorectal carcinoma while 361 studies related to pharmacodynamics remain active and looking for participants."
Has research been conducted on the pharmacodynamic profile of this drug?
"At the moment, 361 Pharmacodynamic Study trials are in progress. Of these, 75 have reached Phase 3 status. Even though a majority of these trials originate from Pittsburgh, Pennsylvania, there are 12308 sites worldwide conducting clinical research for this medication."
What is the upper limit for participants in this experiment?
"At present, no new participants are being sought for this study which was initially advertised on December 27th 2017 and last updated on August 4th 2022. However, there are 858 clinical trials actively recruiting patients with colorectal carcinoma as well as 361 studies in search of volunteers to participate in a Pharmacodynamic Study."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger